Development of Translatable Immunologically Safe PEGylated Lipid Nanoparticles for mRNAVaccine Delivery (2025-2026)

Abstract

The goal of this project is to address emerging concerns regarding the immunosafety of lipid nanoparticles (LNPs) used in delivering mRNA vaccines, particularly focusing on the immunogenicity triggered by poly(ethylene glycol) (PEG), a crucial hydrophilic polymer stabiliser used in LNP formulations. We propose substituting the immunogenic PEG in LNP formulations with a superior class of hydrophilic sulfoxide polymers that demonstrate enhanced stealth performance and lower immunogenic risk. Through this substitution, the project will develop advanced LNPs with improved immunosafety for safer and more effective delivery of mRNA vaccines.

Experts

Dr Changkui Fu

NHMRC Emerging Leadership Fellow: Australian Institute for Bioengineering and Nanotechnology

Changkui Fu

Professor Andrew Whittaker

Affiliate of Australian Research Council Centre of Excellence for Green Electrochemical Transformati: ARC COE for Green Electrochemical Transformation of Carbon Dioxide; Faculty of Engineering, Architecture and Information Technology

Affiliate Professor: School of Chemistry and Molecular Biosciences; Faculty of Science

Professorial Research Fellow and Senior Group Leader: Australian Institute for Bioengineering and Nanotechnology

Andrew Whittaker

Professor Megan O'Mara

Affiliate of ARC COE for Innovations in Peptide and Protein Science: ARC COE for Innovations in Peptide and Protein Science; Institute for Molecular Bioscience

Affiliate Professor of School of Chemistry and Molecular Biosciences: School of Chemistry and Molecular Biosciences; Faculty of Science

Professorial Research Fellow and Group Leader: Australian Institute for Bioengineering and Nanotechnology

Megan O'Mara